ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
122.350,38
0,92%
S&P 500
5.996,66
1,00%
US Dollar vs BRL
6,08068
0,00%
Bitcoin
103.218,35
-0,87%
Brent Oil
80,005
0,00%
As Melhores Corretoras Online
Registration Strip Icon for tools Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Werewolf Therapeutics Inc (HOWL)

  7. Werewolf Therapeutics Inc (HOWL) Notícias

HOWL

Werewolf Therapeutics (HOWL)

Werewolf Therapeutics Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:HOWL
DataHoraFonteTítuloCódigoCompanhia
13/01/202510:00GlobeNewswire Inc.Werewolf Therapeutics Provides Business Update and Highlights 2025 Strategic OutlookNASDAQ:HOWLWerewolf Therapeutics Inc
06/01/202519:51Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HOWLWerewolf Therapeutics Inc
20/11/202410:00GlobeNewswire Inc.Werewolf Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Healthcare ConferenceNASDAQ:HOWLWerewolf Therapeutics Inc
07/11/202411:09Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:HOWLWerewolf Therapeutics Inc
07/11/202411:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:HOWLWerewolf Therapeutics Inc
07/11/202411:02GlobeNewswire Inc.Werewolf Therapeutics Presents Preclinical and Clinical Data at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual MeetingNASDAQ:HOWLWerewolf Therapeutics Inc
07/11/202411:00GlobeNewswire Inc.Werewolf Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:HOWLWerewolf Therapeutics Inc
31/10/202409:00GlobeNewswire Inc.Werewolf Therapeutics Announces Promising New Development Candidate, WTX-921, a first-of-its-kind IL-10 INDUKINE™ Molecule for Inflammatory DiseasesNASDAQ:HOWLWerewolf Therapeutics Inc
04/10/202410:00GlobeNewswire Inc.Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual MeetingNASDAQ:HOWLWerewolf Therapeutics Inc
03/09/202409:00GlobeNewswire Inc.Werewolf Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment ConferenceNASDAQ:HOWLWerewolf Therapeutics Inc
08/08/202408:21Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:HOWLWerewolf Therapeutics Inc
08/08/202408:05GlobeNewswire Inc.Werewolf Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:HOWLWerewolf Therapeutics Inc
25/06/202408:00GlobeNewswire Inc.Werewolf Therapeutics Highlights Initial Safety and Efficacy Data from its Ongoing Phase 1 Clinical Trial Evaluating WTX-330 in Patients with Advanced or Metastatic Solid Tumors or Non-Hodgkin LymphomaNASDAQ:HOWLWerewolf Therapeutics Inc
01/06/202410:00GlobeNewswire Inc.Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid TumorsNASDAQ:HOWLWerewolf Therapeutics Inc
30/05/202409:00GlobeNewswire Inc.Werewolf Therapeutics to Participate at the Jefferies Global Healthcare ConferenceNASDAQ:HOWLWerewolf Therapeutics Inc
23/05/202418:00GlobeNewswire Inc.Werewolf Therapeutics to Present Updated Data from Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors at 2024 ASCO Annual MeetingNASDAQ:HOWLWerewolf Therapeutics Inc
03/05/202408:00GlobeNewswire Inc.Werewolf Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:HOWLWerewolf Therapeutics Inc
24/04/202411:05GlobeNewswire Inc.Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingNASDAQ:HOWLWerewolf Therapeutics Inc
23/04/202409:00GlobeNewswire Inc.Werewolf Therapeutics Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease (IBD) at AAI Annual MeetingNASDAQ:HOWLWerewolf Therapeutics Inc
05/04/202417:30GlobeNewswire Inc.Werewolf Therapeutics Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics WTX-518 and WTX-712 at AACR 2024 Annual MeetingNASDAQ:HOWLWerewolf Therapeutics Inc
04/04/202417:30GlobeNewswire Inc.Werewolf Therapeutics to Present First-of-Its-Kind Data Demonstrating Utility for PREDATOR™ Platform in Immunology-Based Diseases at AAI Annual MeetingNASDAQ:HOWLWerewolf Therapeutics Inc
07/03/202409:22Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:HOWLWerewolf Therapeutics Inc
07/03/202409:15Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:HOWLWerewolf Therapeutics Inc
07/03/202409:00GlobeNewswire Inc.Werewolf Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:HOWLWerewolf Therapeutics Inc
06/03/202410:00GlobeNewswire Inc.Werewolf Therapeutics to Present at the 2024 Leerink Partners Global Biopharma ConferenceNASDAQ:HOWLWerewolf Therapeutics Inc
05/03/202418:30GlobeNewswire Inc.Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2024NASDAQ:HOWLWerewolf Therapeutics Inc
09/02/202418:35Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:HOWLWerewolf Therapeutics Inc
04/01/202421:13Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:HOWLWerewolf Therapeutics Inc
04/01/202418:05GlobeNewswire Inc.Werewolf Therapeutics Appoints Michael Atkins, M.D., to its Board of DirectorsNASDAQ:HOWLWerewolf Therapeutics Inc
22/11/202309:00GlobeNewswire Inc.Werewolf Therapeutics to Present at the Evercore ISI HealthCONx ConferenceNASDAQ:HOWLWerewolf Therapeutics Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:HOWL

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
BRAV3
Brava Energia ON
BOV
FNAM11
Fundo Invest Amazonia Fi...
BOV
AMOB3
Automob Participacoes ON
BOV
PMAM3
PARANAPANEMA ON
BOV
PCAR3
PÃO DE AÇUCAR ON
BOV
COGN3
COGNA ON
BOV
HBRE3
HBR Realty Empreendiment... ON
BOV
AMER3
Americanas ON
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2025 ADVFN PLC - Todos os direitos reservados